MEDIA

EVENTS

The European Medicines Agency (EMA) has officially released its final "Reflection paper on the use of Artificial Intelligence (AI) in the medicinal product lifecycle" following a public consultation period.
This paper explores the potential applications and regulatory considerations for AI across the lifecycle of medicinal products, from drug discovery and clinical trials to post-authorisation activities such as pharmacovigilance.
Notably, the reflection paper highlights important considerations for data quality and representativeness in case of small populations: AI systems, particularly those used in clinical trials and treatment optimisation, must be carefully monitored to avoid biases that could affect minority groups, including children and individuals with rare diseases, that may be underrepresented in training datasets.
The paper encourages early engagement with regulatory bodies to address the potential risks associated with AI, particularly in high-risk patient groups.

Subscribe To Our Newsletter

to keep you up to date on our activities and initiatives

La tua iscrizione non può essere convalidata.
La tua iscrizione è avvenuta correttamente.

We use Brevo as our marketing platform. By clicking below to submit this form, you are aware and accept that the information you have provided will be transferred to Brevo for treatment in accordance with their terms of use
Utilizziamo Brevo come nostra piattaforma di marketing. Cliccando qui sotto per inviare questo modulo, sei consapevole e accetti che le informazioni che hai fornito verranno trasferite a Brevo per il trattamento conformemente alle loro condizioni d'uso

You have Successfully Subscribed!